Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cross-border M&A wizardry produces Valneva from Vivalis & Intercell

This article was originally published in Scrip

Executive Summary

Technology licensing firm Vivalis of France and vaccine company Intercell of Austria have broken new ground for technical sophistication in engineering a cross-border merger agreement that combines elements of financing and preferred share conditionality. The two companies expect to complete their merger of equals next May to form a new company focused on vaccines and antibodies. It will be called Valneva, headquartered in Lyon, France, and listed on the NYSE Euronext in Paris and the Vienna Stock Exchange.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts